Cargando…

Prostate Cancer Radiotherapy: Increased Biochemical Control and Late Toxicity in Men With Medication Allergies

BACKGROUND: Given similarities in the mediators of medication allergy (MA) and tissue response to radiotherapy, we assessed whether outcomes following prostate radiotherapy differ in patients with MAs. METHODS: A total 587 men with known MA history and nonmetastatic prostate cancer underwent radioth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turchan, William Tyler, Gutiontov, Stanley I, Spiotto, Michael T, Liauw, Stanley L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771007/ https://www.ncbi.nlm.nih.gov/pubmed/33409456 http://dx.doi.org/10.1093/jncics/pkaa081

Ejemplares similares

Improved outcomes after radiotherapy for prostate cancer: Anticoagulation, antiplatelet therapy, and platelet count as key factors in disease progression
por: Gutiontov, Stanley I., et al.
Publicado: (2020)

Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer
por: Solanki, Abhishek A, et al.
Publicado: (2011)

Patterns of Care and Outcomes of Intensity-Modulated Radiotherapy and 3D Conformal Radiotherapy for Early Stage Glottic Cancer: A National Cancer Database Analysis
por: Korpics, Mark C., et al.
Publicado: (2019)

Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy
por: Chennupati, Sravana K, et al.
Publicado: (2014)

A Contemporary Report of Low-Dose-Rate Brachytherapy for Prostate Cancer Using MRI for Risk Stratification: Disease Outcomes and Patient-Reported Quality of Life †
por: Patel, Mira, et al.
Publicado: (2023)

Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy
por: Turchan, William Tyler, et al.
Publicado: (2022)

Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer
por: Choe, Kevin S., et al.
Publicado: (2010)

Predictors for late genitourinary toxicity in men receiving radiotherapy for high-risk prostate cancer using planned and accumulated dose
por: Li Kuan Ong, Ashley, et al.
Publicado: (2023)

Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines
por: Akthar, Adil S., et al.
Publicado: (2018)

Predicting Radiotherapy Impact on Late Bladder Toxicity in Prostate Cancer Patients: An Observational Study
por: Catucci, Francesco, et al.
Publicado: (2021)

Proton Radiotherapy to Reduce Late Complications in Childhood Head and Neck Cancers
por: Spiotto, Michael T., et al.
Publicado: (2021)

Dose-volume analysis of planned versus accumulated dose as a predictor for late gastrointestinal toxicity in men receiving radiotherapy for high-risk prostate cancer
por: Ong, Ashley L.K, et al.
Publicado: (2022)

Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma
por: Sanguineti, G, et al.
Publicado: (2002)

Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer
por: Peach, Matthew Sean, et al.
Publicado: (2015)

Comparison of 3D Confromal Radiotherapy and Intensity Modulated Radiotherapy with or without Simultaneous Integrated Boost during Concurrent Chemoradiation for Locally Advanced Head and Neck Cancers
por: Spiotto, Michael T., et al.
Publicado: (2014)

Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity
por: Thomson, David, et al.
Publicado: (2012)

Predictive modelling for late rectal and urinary toxicities after prostate radiotherapy using planned and delivered dose
por: Ong, Ashley Li Kuan, et al.
Publicado: (2022)

Biochemical failure and toxicity in treatment with brachytherapy and external beam radiotherapy compared with radical prostatectomy in localized prostate cancer
por: Galdos-Bejar, Marcelo, et al.
Publicado: (2022)

Stereotactic ablative body radiotherapy in patients with prostate cancer
por: Loblaw, Andrew, et al.
Publicado: (2018)

Clinical Outcomes for Gastric Cancer following Adjuvant Chemoradiation Utilizing Intensity Modulated versus Three-Dimensional Conformal Radiotherapy
por: Liu, Gene-Fu F., et al.
Publicado: (2014)

Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy
por: Kerns, Sarah L, et al.
Publicado: (2019)

Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity
por: Ahmed, Mahbubl, et al.
Publicado: (2016)

Impact of age on treatment response in men with prostate cancer treated with radiotherapy
por: Bryant, Alex K., et al.
Publicado: (2021)

1805. Safety Outcomes Following Beta-Lactam use in Patients with a Documented Beta-Lactam Allergy
por: Rampersad, Daniel, et al.
Publicado: (2022)

Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer
por: Kerns, Sarah L., et al.
Publicado: (2016)

Acute and late toxicity patterns of moderate hypo-fractionated radiotherapy for prostate cancer: A systematic review and meta-analysis
por: Sinzabakira, F., et al.
Publicado: (2023)

Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial
por: Kim, Julian O., et al.
Publicado: (2021)

Older Age, Early Symptoms and Physical Function are Associated with the Severity of Late Symptom Clusters for Men Undergoing Radiotherapy for Prostate Cancer
por: Lemanska, A., et al.
Publicado: (2018)

Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate
por: Roy, Soumyajit, et al.
Publicado: (2023)

Dosimetric correlation of acute and late toxicities in high-risk prostate cancer patients treated with three-dimensional conformal radiotherapy followed by intensity modulated radiotherapy boost
por: Kapoor, Rakesh, et al.
Publicado: (2016)

Radiotherapy for elder patients aged ≥80 with clinically localized prostate cancer – Brachytherapy enhanced late GU toxicity especially in elderly
por: Yamazaki, Hideya, et al.
Publicado: (2020)

Local Dose Effects for Late Gastrointestinal Toxicity After Hypofractionated and Conventionally Fractionated Modern Radiotherapy for Prostate Cancer in the HYPRO Trial
por: Heemsbergen, Wilma D., et al.
Publicado: (2020)

Hematologic Toxicity of Conformal Radiotherapy and Intensity Modulated Radiotherapy in Prostate and Bladder Cancer Patients
por: Miszczyk, Marcin, et al.
Publicado: (2018)

Utilizing the TrueBeam Advanced Imaging Package to monitor intrafraction motion with periodic kV imaging and automatic marker detection during VMAT prostate treatments
por: Korpics, Mark C., et al.
Publicado: (2020)

Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry
por: Davis, Joanne, et al.
Publicado: (2015)

Nomogram to predict rectal toxicity following prostate cancer radiotherapy
por: Delobel, Jean-Bernard, et al.
Publicado: (2017)

Radiotherapy-induced toxicity in prostate cancer patients with hip prostheses
por: Fischer, Andrea M., et al.
Publicado: (2022)

Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy
por: Valle, Luca F., et al.
Publicado: (2020)

THE PLACENTAL TRANSMISSION OF ANTIBODIES IN THE SKIN SENSITIVE TYPE OF HUMAN ALLERGY
por: Sherman, William B., et al.
Publicado: (1940)

Comparison of biochemical recurrence in prostate cancer patients treated with radical prostatectomy or radiotherapy
por: Kim, Dong Soo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_m6bpi431gkn5pfnosubj6s5il3